Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRI NASDAQ:CYCN NASDAQ:PTIX NYSEAMERICAN:SVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.88+2.4%$0.87$0.54▼$2.22$8.93M0.5268,938 shs55,073 shsCYCNCyclerion Therapeutics$2.62+2.0%$2.85$1.27▼$9.47$8.75M1.68740,510 shs64,078 shsPTIXAtrinsic$3.58-8.3%$3.34$2.25▼$15.54$2.11M0.341.89 million shs242,418 shsSVTServotronics$46.94$46.94$9.67▼$47.48$120.17M1.4912,160 shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera-4.44%-2.28%-19.63%+40.94%-21.82%CYCNCyclerion Therapeutics-6.88%+7.98%-7.55%-9.82%-6.55%PTIXAtrinsic-1.76%+71.05%+18.90%+2.36%-53.57%SVTServotronics0.00%0.00%0.00%+0.90%+254.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera3.1027 of 5 stars3.55.00.00.03.50.00.6CYCNCyclerion Therapeutics2.5048 of 5 stars0.05.00.00.04.43.30.0PTIXAtrinsic0.7322 of 5 stars0.03.00.00.03.11.70.0SVTServotronicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 3.00Buy$2.75212.15% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/APTIXAtrinsic 0.00N/AN/AN/ASVTServotronics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.24N/AN/A($0.46) per share-1.92CYCNCyclerion Therapeutics$2M4.38N/AN/A$2.57 per share1.02PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASVTServotronics$44.92M2.68$0.07 per share658.77$9.20 per share5.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$17.76M-$2.26N/AN/AN/A-42.34%-1,104.09%-82.28%11/12/2025 (Estimated)CYCNCyclerion Therapeutics-$3.06M-$0.74N/A∞N/A-89.51%-22.63%-20.65%11/12/2025 (Estimated)PTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%11/12/2025 (Estimated)SVTServotronics-$1.62M$0.05N/A∞N/A-2.32%-1.23%-0.82%11/6/2025 (Estimated)Latest PTIX, SVT, CYCN, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BFRIBiofrontera-$0.45-$0.57-$0.12-$0.57$8.30 million$9.03 million8/5/2025Q2 2025CYCNCyclerion TherapeuticsN/A-$0.11N/A-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASVTServotronicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofrontera8.990.960.75CYCNCyclerion TherapeuticsN/A5.035.03PTIXAtrinsicN/A0.860.86SVTServotronicsN/A3.461.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%CYCNCyclerion Therapeutics75.62%PTIXAtrinsic7.97%SVTServotronics24.77%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera4.80%CYCNCyclerion Therapeutics34.30%PTIXAtrinsic35.00%SVTServotronics33.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera7010.14 million9.65 millionNo DataCYCNCyclerion Therapeutics303.34 million2.19 millionNo DataPTIXAtrinsic2590,000383,000Not OptionableSVTServotronics2702.56 million1.69 millionNot OptionablePTIX, SVT, CYCN, and BFRI HeadlinesRecent News About These CompaniesServotronics Completes Merger and Delists SharesJuly 29, 2025 | theglobeandmail.comTransDigm successfully acquires Servotronics in $134M dealJuly 2, 2025 | bizjournals.comServotronics, Inc. (SVT) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comTransDigm completes $134 million Servotronics dealJuly 2, 2025 | buffalonews.comBTransDigm and Servotronics Announce Successful Completion of Tender Offer and TransDigm's Acquisition of ServotronicsJuly 1, 2025 | prnewswire.comStar Equity Fund’s Successful Servotronics Campaign Leads to Acquisition by TransDigm for $47 per ShareJune 30, 2025 | finance.yahoo.comShareholder withdraws court filings seeking to block Servotronics acquisitionJune 20, 2025 | bizjournals.comServotronics shareholder seeks to block TransDigm acquisitionJune 18, 2025 | bizjournals.comTransDigm Group Incorporated acquiring Servotronics, Inc.June 8, 2025 | magnoliareporter.comMInside the bidding war for ServotronicsJune 7, 2025 | buffalonews.comBServotronics Says TransDigm Sweetens Acquisition Offer To $47/Share, Amends AgreementMay 31, 2025 | nasdaq.comServotronics Deal Rewrite Ignites Shareholder ValueMay 29, 2025 | insidermonkey.comServotronics, Inc.: Servotronics Executes Amendment to the Agreement and Plan of Merger with TransDigmMay 29, 2025 | finanznachrichten.deServotronics stock soars on raised takeover bidMay 29, 2025 | za.investing.comServotronics Executes Amendment to the Agreement and Plan of Merger with TransDigmMay 29, 2025 | finance.yahoo.comServotronics Shares Jump Nearly 25% on Upgraded Buyout Offer from TransDigmMay 29, 2025 | msn.comTransDigm raises offer price for Servotronics to $47/shareMay 29, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of ShareholdersMay 29, 2025 | morningstar.comMAskeladden Capital Presents Plan To Maximize AstroNova’s Shareholder ValueMay 23, 2025 | usatoday.comServotronics investor withdraws proxy campaign after acquisition dealMay 22, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, SVT, CYCN, and BFRI Company DescriptionsBiofrontera NASDAQ:BFRI$0.88 +0.02 (+1.74%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Cyclerion Therapeutics NASDAQ:CYCN$2.62 +0.05 (+1.98%) Closing price 03:59 PM EasternExtended Trading$2.61 -0.01 (-0.42%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Atrinsic NASDAQ:PTIX$3.56 -0.34 (-8.59%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Servotronics NYSEAMERICAN:SVT$46.94 0.00 (0.00%) As of 07/1/2025Servotronics, Inc. designs, manufactures, and markets servo-control components and other technology products for aerospace, military, and medical applications in the United States and internationally. It offers high-performance servo valves, including torque motor, hydraulic, and pneumatic valves. The company offers its products to products are sold to commercial aerospace, government, medical, and industrial markets. The company was incorporated in 1959 and is headquartered in Elma, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access